Searchable abstracts of presentations at key conferences in endocrinology

ea0013p181 | Diabetes, metabolism and cardiovascular | SFEBES2007

TRB3: A mechanism for glucocorticoid induced insulin sensitisation in human adipocytes

Gathercole Laura , Bujalska Iwona , Stewart Paul , Tomlinson Jeremy

Glucocorticoid (GC) excess is characterized by central obesity, insulin resistance and in some cases, type 2 diabetes mellitus. Whilst it is accepted that GCs cause insulin resistance, both insulin and GCs act synergistically to promote adipocyte differentiation. We have previously shown that GCs cause tissue specific changes in insulin sensitivity, enhancing insulin signalling in human adipose tissue in contrast to muscle.TRB3, a mammalian homolog of <i...

ea0012p73 | Neuroendocrinology and behaviour | SFE2006

Adrenomedullin in a rat model of multiple sclerosis

Barker S , Mongru R , Bolton C , Paul C

The vasoactive peptide adrenomedullin (ADM) has effects on several vascular beds including the cerebral circulation. The peptide has a positive impact on blood-brain-barrier (BBB) integrity, and transcription of ADM mRNA is enhanced by pro-inflammatory cytokines, IL-1 and TNF-alpha in neuronal cell types. The current study has investigated whether ADM may be a marker for disease progression, in vivo in experimental allergic encephalomyelitis (EAE), a model of the human disease...

ea0056ep16 | Adrenal and Neuroendocrine Tumours | ECE2018

Patient experiences with continouous subcutaneous hydrocortisone infusion (CSHI)

Yeoh Phillip , Khoo Bernard , Carroll Paul , Aylwin Simon

We recently reported the impact of continous s.c. hydrocortisone infusion (CSHI) on weight, patient AddiQoL scores and healthcare cost savings on five patients. This poster is to follow up on all our patients experiences since started on the CSHI as well as qualitative feedback on the impact on their lives.This poster also gathered key points on how these patients managed their adrenal crisis....

ea0045oc6.5 | Oral Communications 6- Endocrine | BSPED2016

A novel methodology using high resolution thermal imaging to detect vertebral fractures in children with osteogenesis imperfecta

De Salis Alexandra Fane , Saatchi Reza , Dimitri Paul

Background: Vertebral compression fractures are common in children with osteogenesis imperfecta. Current imaging methods for fracture detection (X-ray and DXA) use ionising radiation. High Resolution Thermal imaging (HRTI) is a non-invasive, non-ionising method that detects infrared radiation energy emissivity to an accuracy of 0.04 °C, providing a quantitative and qualitative map of temperature distribution. Given that the alteration in blood flow in vertebral fractures ...

ea0073aep40 | Adrenal and Cardiovascular Endocrinology | ECE2021

A Clinically silent, non-secretory phaeochromocytoma

Lewis Megan , Ahmed M Gharib Ahmed , Lambert Paul

Adrenal incidentalomata are a common finding on cross-sectional imaging of the abdomen. Further assessment is required to differentiate benign adrenal masses from adrenocortical carcinomas and hormone-secreting tumours. Phaeochromocytomas are rare catecholamine-secreting tumours arising from chromaffin cells of the adrenal medulla. They classically present with symptoms and signs of catecholamine excess including headache, sweating, hypertension and tachycardia. However, with ...

ea0092ps2-13-06 | Surgery | ETA2023

Prospective implementation of thyroid lobectomy recommendations and thyrospec molecular testing for bethesda III and IV nodules and impact on surgery

Yeo Caitlin , Wu Jiahui , Stewardson Paul , Eszlinger Markus , Paschke Ralf

Objectives: In May 2016, the local thyroid cancer tumor group proposed and adopted specific thyroid lobectomy recommendations based on the 2015 ATA guidelines. ThyroSPEC molecular testing was introduced for all Bethesda III and IV lesions in August 2020. The goal of this study was to evaluate the implementation of the ATA lobectomy guidelines and the introduction of ThyroSPEC molecular testing on rates of upfront total thyroidectomy (TTx), diagnostic lobectomy for Bethesda I-I...

ea0094p198 | Endocrine Cancer and Late Effects | SFEBES2023

Evaluation of a national genetic testing service for monogenic endocrine disease in Scotland; enforcement of referral criteria may result in missed opportunities for genetic diagnosis

Ahmed Sufia , McLean Joanne , Berg Jonathan , Goudie David , Newey Paul

Background: Establishing a genetic diagnosis in patients presenting with potential monogenic endocrine disorders can provide benefits for the individual and wider family. Next-generation sequencing (NGS) gene panels provide a time- and cost-efficient platform for testing. A Scottish NGS endocrine testing platform, comprising 30 genes (11 individual panels), was established in 2018. A national genomic test-directory provides eligibility criteria for testing, bu...

ea0094p51 | Innovation in Teaching | SFEBES2023

Genomic notes for clinicians – A genomic testing resource for endocrinologists

Gohil Shailesh , Korbonits Marta , Casey Ruth , Newey Paul , Levy Miles

Introduction: Genomic testing is expected to become a part of mainstream testing in the not-too-distant future, with clinicians ordering genetics tests in the same way routine endocrine tests are requested today. Knowledge on how and what test to request needs to be gathered by a wide range of physicians. To support this, the Genomics Education Programme of NHS England is developing a resource for all endocrinologists to use in clinic as part it’s Genomic...

ea0094p133 | Thyroid | SFEBES2023

Radioactive iodine (I-131) in hyperthyroidism: Does weight gain remain a risk?

Green Kathryn , Connelly Paul , Tough Jillian , White Anna , Kelly Chris

Background: Radioactive iodine (RAI) is a safe and effective treatment for management of hyperthyroidism caused by Graves’ disease and multinodular goitres. However, patient engagement with this therapy is limited by concerns regarding significant weight gain following treatment. We therefore aimed to audit weight changes in individuals receiving RAI within our service and identify factors that may influence this outcome.Met...

ea0094p137 | Thyroid | SFEBES2023

Combination Levothyroxine and Liothyronine therapy: Evaluation of a new local management pathway

Lin YeunYi , Hernandez Gillian , Leese Graham , Newey Paul , Malik Iqbal

Background: Combination treatment with Levothyroxine (LT4) and Liothyronine (LT3) in primary hypothyroidism has been debated recently due to restrictions placed by local health boards. National guidance suggests that a short-term trial of combination LT4/LT3 treatment may be considered for individuals who report persistent symptoms despite adequate LT4 replacement.Method: We created a prescribing protocol for combined LT...